[Immune checkpoint inhibitors in lung cancer]

Internist (Berl). 2020 Jul;61(7):676-681. doi: 10.1007/s00108-020-00815-y.
[Article in German]

Abstract

Immune checkpoint inhibitors (ICI) have emerged as an important treatment strategy in lung cancer in recent years. Implementation and approval status of each approved ICI will be presented by summarizing the most important phase III studies of nivolumab, pembrolizumab, atezolizumab and durvalumab. ICI are used as mono- or combination therapy with chemotherapy according to programmed cell death 1 ligand 1 (PD-L1) status and therapy line.

Keywords: Immunotherapy; Non-small cell lung cancer; Programmed cell death 1 ligand 1 (PD-L1); Small cell lung cancer; Tumor mutational burden.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use*
  • Antineoplastic Agents / therapeutic use*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / immunology
  • Carcinoma, Non-Small-Cell Lung / metabolism
  • Combined Modality Therapy
  • Humans
  • Immunologic Factors
  • Immunotherapy*
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / immunology
  • Lung Neoplasms / metabolism
  • Nivolumab / therapeutic use*

Substances

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Immunologic Factors
  • Nivolumab